Selçuk Ecza Deposu stock (TRASELEC91C3): Turkish pharmacy chain in focus after latest results

Selçuk Ecza Deposu reported its latest quarterly results, highlighting revenue growth and margin trends in Turkey’s pharmacy retail sector.

Selçuk Ecza Deposu, a leading Turkish pharmacy chain operator, has drawn investor attention after the release of its most recent quarterly financial results. The company reported year?on?year revenue growth and maintained its position as one of the larger pharmacy networks in Turkey, according to its latest investor presentation and financial statements published on its investor relations site.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

As of: 10.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Selçuk Ecza Deposu
• Sector/industry: Healthcare retail / pharmacy chain
• Headquarters/country: Turkey
• Core markets: Turkey
• Key revenue drivers: Pharmacy retail sales, over?the?counter products, prescription dispensing
• Home exchange/listing venue: Borsa Istanbul (ticker: SELEC)
• Trading currency: Turkish lira (TRY)

Selçuk Ecza Deposu: core business model

Selçuk Ecza Deposu operates a nationwide network of pharmacies under the Selçuk Ecza brand, focusing on retail pharmacy services in urban and regional centers across Turkey. The company’s business model centers on high?volume, low?margin sales of prescription and non?prescription medicines, health and beauty products, and related consumer goods, supported by a centralized logistics and procurement infrastructure.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

The company leverages its scale to negotiate favorable terms with pharmaceutical suppliers and distributors, which helps maintain competitive pricing for customers while supporting gross margin stability. In addition to in?store sales, Selçuk Ecza Deposu has expanded digital channels and home?delivery options, aligning with broader trends in healthcare retail toward omnichannel access.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

Main revenue and product drivers for Selçuk Ecza Deposu

Pharmacy retail sales form the core of Selçuk Ecza Deposu’s revenue, with prescription medicines and over?the?counter products accounting for the largest share. The company benefits from Turkey’s growing population, rising healthcare awareness, and an aging demographic, all of which support steady demand for medicines and health?related products.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

Non?pharmaceutical categories such as cosmetics, personal care, vitamins, and baby products also contribute meaningfully to sales, often at higher margins than core pharmaceuticals. The company’s strategy includes optimizing product mix, expanding private?label offerings, and enhancing in?store promotions to drive basket size and customer loyalty.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

Conclusion

Selçuk Ecza Deposu remains a prominent player in Turkey’s pharmacy retail landscape, supported by a large store network and a diversified product mix. The company’s latest results underscore ongoing revenue growth and margin discipline, even as it navigates macroeconomic pressures in the Turkish market.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

For US investors, exposure to Selçuk Ecza Deposu is typically indirect, via emerging?market or Turkey?focused funds rather than direct listings on US exchanges. This adds currency and country?risk considerations, alongside the usual volatility associated with retail and healthcare stocks.Selçuk Ecza Deposu Investor Relations as of 05/10/2026

This article does not constitute investment advice. Stocks are volatile financial instruments.